

Cached messages

Message 6 of 7 in conversation

[« Older](#) | [Newer »](#) [View Entire Thread \(7\)](#) [Reply](#) | [Reply to all](#) | [Forward](#) | [View in Outlook](#)

· RE: Visit to San Diego

From: Cartt, Steve <SCartt@questcor.com>
To: Ralph Barry <rbarry@aegisthera.com>
CC: Ed Maggio <Edaegis@san.rr.com>
Date: Mar 26 2007 - 5:12pm

My mistake. I meant Wednesday April 4 at 10 am. Let's put that in the calendar.
Thanks, Steve

From: Ralph Barry [mailto:rbarry@aegisthera.com]
Sent: Monday, March 26, 2007 4:38 PM
To: Cartt, Steve
Cc: Ed Maggio; Ralph Barry
Subject: Re: Visit to San Diego

Steve:

I hope you had a great weekend. My calendar shows that Tuesday is April 3 and Wednesday is April 4, but either day at 10 AM works for us. Just let me know.

Ralph

Cartt, Steve wrote:

Ed/Ralph – how about Wednesday April 3 at 10 am? Please let me know. Thanks,
Steve

From: Ed Maggio [mailto:Edaegis@san.rr.com]
Sent: Monday, March 26, 2007 9:35 AM
To: Cartt, Steve
Cc: 'Edward Maggio'; 'Ralph Barry'
Subject: RE: Visit to San Diego

Hi Steve:

Monday, April 2nd, Tuesday AM up to about 11:00AM or after 3PM, and Wednesday and Thursday are open at present.

Ed

From: Cartt, Steve [mailto:SCartt@questcor.com]
Sent: Friday, March 23, 2007 4:47 PM
To: Ralph Barry
Cc: Edward Maggio
Subject: Visit to San Diego

Ralph and Ed:

It was good talking to you today. As I mentioned, I will be in San Diego for meetings the week of April 2. If possible, I would like to come by Aegis to talk in person about this potential project. Please let me know what days/times you are available.

Have a great weekend,

Steve

Ralph R. Barry
Chief Business Officer
Aegis Therapeutics, LLC
16870 West Bernardo Drive, Suite 390
San Diego, CA 92127

Phone: 858-618-1400, Extension 102
Mobile: 858-735-2398
Facsimile: 858-618-1441
Website: HYPERLINK "<http://www.aegisthera.com>"www.aegisthera.com.

Aegis Therapeutics is a drug delivery technology company commercializing patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Our ProTek™ technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek™ technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

This message and any attachments thereto may contain private, confidential, and privileged material for the sole use of the intended recipient. Any review, copying, or distribution of this facsimile (or any attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please contact the sender immediately.

[« Older](#) | [Newer »](#) [View Entire Thread \(7\)](#) [Reply](#) | [Reply to all](#) | [Forward](#) | [View in Outlook](#)

Questcor

Search

[Google Desktop Home](#) - [Browse Timeline](#) - [Index Status](#) - [Privacy](#) - [About](#) - ©2009 Google